O'NEIL, JAMES DENNEN,SHARMA, SHALINI,ARUDCHANDRAN, RAMACHANDRAN
申请号：
CA2722624
公开号：
CA2722624C
申请日:
2009.04.30
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Uric acid in mammalian subjects is reduced and excretion of uric acid isincreased by administering a compound ofFormula I. The uric acid-lowering effects of the compounds of this inventionare used to treat or prevent a variety of conditions in-cludinggout, hyperuricemia, elevated levels of uric acid that do not meet the levelscustomarily justifying a diagnosis of hyper-uricemia,renal dysfunction, kidney stones, cardiovascular disease, risk for developingcardiovascular disease, tumor-lysis syn-drome,cognitive impairment, early-onset essential hypertension, and Plasmodiumfalciparum-induced inflammation. In Formula1, x is 1 or 2: y is 0, 1, 2 or 3； and R1 is selected from the groupconsisting of hydrogen, alkyl having 1 or 2 carbon atoms, hy-droxy,alkoxy having 1 or 2 carbon atoms, fluoro. chloro, bromo, and amino. A isphenyl unsubstituted or substituted by one, twoor three groups selected from the group consisting of halo, alkyl having 1 or2 carbon atoms. perfluoromethyL alkoxy having 1 or2 carbon atoms, and perfluoromethoxy； or cycloalkyl having from 3 to 6 ringatoms wherein the cycloalky! is unsubstituted or oneone two ring carbons are independently mono-substituted by methyl or ethyl； ora 5 or 6 membered heleraromatic ring having 1 or2 ring heteroatoms selected from N. S and 0 and the heteroaromatic ring iscovalently bound to the remainder of the compound bya ring carbon.
